pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2495Research ArticleОБЗОРЫREVIEWВозможность достижения контроля над бронхиальной астмой при использовании гибкого дозирования препарата Симбикорт у пациентов со среднетяжелой и тяжелой бронхиальной астмой. Данные исследования SUNDAchieving asthma control with flexible dosing of Simbicort in moderate to severe bronchial asthma patients. Findings of SUND study.КняжескаяН. В.KnyazheskayaN. P.
Кафедра пульмонологии
ПотаповаМ. О.PotapovaM. O.
Москва
ФУВ РГМУRussian FederationЦентральная клиническая больница с поликлиникой, Медицинский центр Управления делами Президента РФRussian Federation20041708202106118124Copyright © Княжеская Н.В., Потапова М.О., 20212021Княжеская Н.В., Потапова М.О.Knyazheskaya N.P., Potapova M.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2495
.
ReferencesЧучалин А.Г. (ред.) Глобальная стратегия лечения и профилактики бронхиальной астмы. М: Атмосфера; 2002.Чучалин А.Г. (ред.) Глобальная стратегия лечения и профилактики бронхиальной астмы. М: Атмосфера; 2002.Чучалин А.Г. (ред.). Клинические рекомендации. Бронхиальная астма у взрослых. Атопический дерматит. М.: Атмосфера; 2002.Чучалин А.Г. (ред.). Клинические рекомендации. Бронхиальная астма у взрослых. Атопический дерматит. М.: Атмосфера; 2002.Haughney J., Barnes G., Partridge M. Living and breathing — a national survey of patients' views of asthma and its treatment. Thorax 2001; 56 (suppl. Ill): S51.Haughney J., Barnes G., Partridge M. Living and breathing — a national survey of patients' views of asthma and its treatment. Thorax 2001; 56 (suppl. Ill): S51.Charlton I., Charlton G., Broomfield J., Mullee M.A. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. Br. Med. J. 1990; 301: 1355-1359.Charlton I., Charlton G., Broomfield J., Mullee M.A. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. Br. Med. J. 1990; 301: 1355-1359.Gibson P.G., Coughlan J., Wilson A.J. et al. Self-management education and regular practitioner review for adults with asthma (Cochrane review). In: The Cochrane library. Oxford: The Cochrane Library; 2003; Issue 4.Gibson P.G., Coughlan J., Wilson A.J. et al. Self-management education and regular practitioner review for adults with asthma (Cochrane review). In: The Cochrane library. Oxford: The Cochrane Library; 2003; Issue 4.Lahdensuo A., Haahtela T., Herrala J. et al. Randomised comparison of guided self-management and traditional treatment of asthma over one year. Br. Med. J. 1996; 312: 748-752.Lahdensuo A., Haahtela T., Herrala J. et al. Randomised comparison of guided self-management and traditional treatment of asthma over one year. Br. Med. J. 1996; 312: 748-752.Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802-807.Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802-807.Bowler S. Inhaled steroids in asthma. Should the dose be reduced? Aus Fam. Physic 2002; 31 (8): 746-748.Bowler S. Inhaled steroids in asthma. Should the dose be reduced? Aus Fam. Physic 2002; 31 (8): 746-748.Barnes P.J., O'Byrn P.M., Rodrigues-Rolsin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomised trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-1397.Barnes P.J., O'Byrn P.M., Rodrigues-Rolsin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomised trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-1397.Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting P2-agonists and corticosteroids. Eur. Respir. J. 2002; 19: 182-191.Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting P2-agonists and corticosteroids. Eur. Respir. J. 2002; 19: 182-191.Greening A.P., Ind P.W., Northfield M., Shaw G. Added sal-meterol versus higher-dose corticosteroid in asthma patients with symptoms on existing ICS. Lancet 1994; 344: 219-224.Greening A.P., Ind P.W., Northfield M., Shaw G. Added sal-meterol versus higher-dose corticosteroid in asthma patients with symptoms on existing ICS. Lancet 1994; 344: 219-224.O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-1397.O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-1397.Pauwels P.A., Lofdahl C.-G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-1411.Pauwels P.A., Lofdahl C.-G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-1411.Woolcock A., Lundback B., Rlngdal N.. Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-1488.Woolcock A., Lundback B., Rlngdal N.. Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-1488.Zetterstrom O., Buhl R., Mellem H. et al. Symbicort® (budesonide and formoterol in a single inhaler) improves asthma control in adults: a randomized controlled study. Eur. Respir. J. 2001; 18: 262-268.Zetterstrom O., Buhl R., Mellem H. et al. Symbicort® (budesonide and formoterol in a single inhaler) improves asthma control in adults: a randomized controlled study. Eur. Respir. J. 2001; 18: 262-268.Chapman K.R., Ringdal N.. Backer V. et al. Salmeterol and fluticasone propionate (50/250 meg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6: 45-51.Chapman K.R., Ringdal N.. Backer V. et al. Salmeterol and fluticasone propionate (50/250 meg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6: 45-51.Balanag V.M., Yunus F., Yang P.-С., Jorup C. Budesonide/for-moterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur. Respir. J. 2003; 22 (suppl. 45): 445s. [Abstr. No. Р2836].Balanag V.M., Yunus F., Yang P.-С., Jorup C. Budesonide/for-moterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur. Respir. J. 2003; 22 (suppl. 45): 445s. [Abstr. No. Р2836].Gustafsson D., Olsson P., Stallberg B. et al. Budesonide/for-moterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study. Eur. Respir. J. 2003; 22 (suppl. 45): 258s. [Abstr. No. Р1697].Gustafsson D., Olsson P., Stallberg B. et al. Budesonide/for-moterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study. Eur. Respir. J. 2003; 22 (suppl. 45): 258s. [Abstr. No. Р1697].Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160:244-249.Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160:244-249.Leuppi J.D., Salzberg M., Meyer L. et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss. Med. Wkly 2003; 133: 302-309.Leuppi J.D., Salzberg M., Meyer L. et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss. Med. Wkly 2003; 133: 302-309.Sears M.R., McOvorA., Becker A. et al. Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study. Eur. Respir. J. 2003; 22 (suppl. 45): 258s. [Abstr. No. Р1695].Sears M.R., McOvorA., Becker A. et al. Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study. Eur. Respir. J. 2003; 22 (suppl. 45): 258s. [Abstr. No. Р1695].FitzGerald J.M., Becker A., Chung K., Lee J. Randomised, controlled, multi-centre study to compare double-dose versus maintenance dose of inhaled corticosteroids (ICS) during asthma exacerbations. Am. J. Respir. Crit. Care Med. 2000; 161: A187FitzGerald J.M., Becker A., Chung K., Lee J. Randomised, controlled, multi-centre study to compare double-dose versus maintenance dose of inhaled corticosteroids (ICS) during asthma exacerbations. Am. J. Respir. Crit. Care Med. 2000; 161: A187FitzGerald M.J., Sears M.R., Boulet L.-P. et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing. A 5-month multicentre Canadian study. Can. Respir. J. 2003; 10 (in press).FitzGerald M.J., Sears M.R., Boulet L.-P. et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing. A 5-month multicentre Canadian study. Can. Respir. J. 2003; 10 (in press).Foresi A., Morelli M.C., Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 440-446.Foresi A., Morelli M.C., Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 440-446.Ringdal N., Chuchalin A., Chovan L. et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250(mcg bd Diskus™ versus formoterol (12 meg bd) and budesonide (800 meg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir. Med. 2002; 96: 851-861.Ringdal N., Chuchalin A., Chovan L. et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250(mcg bd Diskus™ versus formoterol (12 meg bd) and budesonide (800 meg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir. Med. 2002; 96: 851-861.Moretti AM., Canonica G.W., Sanguinetti CM. et al. Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study. Eur. Respir. J. 2003; 22 (suppl. 45): 259s. [Abstr. No. Р1703].Moretti AM., Canonica G.W., Sanguinetti CM. et al. Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study. Eur. Respir. J. 2003; 22 (suppl. 45): 259s. [Abstr. No. Р1703].Olsson P., Karlsson G., Ekstrom T., Lindarck N. Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen. Eur. Respir. J. 2003; 22 (suppl. 45): 411s. [Abstr. No. Р2643].Olsson P., Karlsson G., Ekstrom T., Lindarck N. Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen. Eur. Respir. J. 2003; 22 (suppl. 45): 411s. [Abstr. No. Р2643].Stallberg B., Olsson P., Jorgensen L.A. et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int. J. Clin. Pract. 2003; 57: 656-661.Stallberg B., Olsson P., Jorgensen L.A. et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int. J. Clin. Pract. 2003; 57: 656-661.Van der Woude H.J., Boorsma M., Bergqvist P.B.F. et al. Budesonide/formoterol in a single inhaler rapidly relieves metha-choline-induced moderate-to-severe bronchoconstriction. Pulm. Pharmacol. Ther. 2004 (in press).Van der Woude H.J., Boorsma M., Bergqvist P.B.F. et al. Budesonide/formoterol in a single inhaler rapidly relieves metha-choline-induced moderate-to-severe bronchoconstriction. Pulm. Pharmacol. Ther. 2004 (in press).Liljas B., Lahdensuo A. Is asthma self-management cost-effective? Patient Educ. Couns. 1997; 32 (suppl. 1): S97-S104.Liljas B., Lahdensuo A. Is asthma self-management cost-effective? Patient Educ. Couns. 1997; 32 (suppl. 1): S97-S104.Aalbers R., Backer V., Kava T. T. K. et al. Adjustable dosing with budesonide/formoterol reduces the rate of exacerbations compared with fixed dosing salmeteroi/fluticasone. Allergy Clin. Immunol. Int. — J. Wld Allergy Org. 2003; 15 (suppl. 1): 50. [Abstr. and poster],Aalbers R., Backer V., Kava T. T. K. et al. Adjustable dosing with budesonide/formoterol reduces the rate of exacerbations compared with fixed dosing salmeteroi/fluticasone. Allergy Clin. Immunol. Int. — J. Wld Allergy Org. 2003; 15 (suppl. 1): 50. [Abstr. and poster],Aalbers R., Backer V., Kava T.T.K. et al. Curr. Med. Res. Opin. 2004; 20 (2): 225-240.Aalbers R., Backer V., Kava T.T.K. et al. Curr. Med. Res. Opin. 2004; 20 (2): 225-240.
The authors declare that there are no conflicts of interest present.